Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$261 Mln
Revenue (TTM)
$41 Mln
Net Profit (TTM)
$0 Mln
ROE
-2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
9.4
Industry P/E
--
EV/EBITDA
-1.4
Div. Yield
0 %
Debt to Equity
2.8
Book Value
$0.3
EPS
$-1.8
Face value
--
Shares outstanding
97,871,999
CFO
$-812.95 Mln
EBITDA
$-1,259.00 Mln
Net Profit
$-1,189.60 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Editas Medicine (EDIT)
| 30.2 | 21.4 | 30.2 | 136.3 | -28.3 | -42.6 | -23.1 |
|
BSE Sensex*
| -13.8 | -8.8 | -14.6 | -3.2 | 6.9 | 8.2 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Editas Medicine (EDIT)
| 61.4 | -87.2 | 14.2 | -66.6 | -62.1 | 136.8 | 30.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Editas Medicine (EDIT)
|
2.7 | 261.3 | 40.5 | -160.1 | -379.8 | -198.1 | -- | 9.4 |
| 61.0 | 8,546.2 | 1,091.0 | 202.3 | 31.6 | 31.3 | 38.1 | 15.0 | |
| 229.3 | 14,074.4 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.7 | 8,218.7 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.5 | |
| 43.9 | 11,764.8 | 2,320.1 | 782.6 | 39.0 | 35.5 | 15.8 | 5.3 | |
| 93.8 | 12,307.7 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 60.9 | |
| 546.9 | 12,545.6 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 20.8 | |
| 498.3 | 14,143.5 | 2,530.2 | 451.1 | 21.3 | 70.2 | 32.7 | 30.2 | |
| 105.4 | 8,288.6 | 0.0 | -425.4 | -- | -36.7 | -- | 6.7 | |
| 310.4 | 8,644.3 | 0.0 | -303.3 | -- | -45.8 | -- | 10.1 |
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead... program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. Read more
President, CEO & Director
Dr. Gilmore O'Neill M.D.
President, CEO & Director
Dr. Gilmore O'Neill M.D.
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Editas Medicine Inc (EDIT) is $2.67 (NASDAQ) as of 02-Apr-2026 19:17 EDT. Editas Medicine Inc (EDIT) has given a return of -28.32% in the last 3 years.
Since, TTM earnings of Editas Medicine Inc (EDIT) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-1.14
|
6.67
|
|
2024
|
-0.44
|
0.78
|
|
2023
|
-5.40
|
2.37
|
|
2022
|
-2.99
|
1.69
|
|
2021
|
-9.80
|
3.28
|
The 52-week high and low of Editas Medicine Inc (EDIT) are Rs 4.54 and Rs 0.91 as of 06-Apr-2026.
Editas Medicine Inc (EDIT) has a market capitalisation of $ 261 Mln as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Editas Medicine Inc (EDIT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.06
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.